Announced details
Medical Support business; blood-derived processing services
Cumulative number of contracted blood-processing cases: 20,000. CAGR over the past 3 years: more than 99%, approximately eightfold. Number of partner clinics: 800 as of April 2026; CAGR over the past 3 years: more than 70%, more than fivefold.
Cumulative number of contracted blood-processing cases: 20,000 (as of May 2026)
Collaboration partner. Collaboration covers customer-base acquisition, integration of the sales channel, and expansion of processing capacity.
SBCメディカルグループ株式会社 and its group companies. Other information, including the location, representative, business activities, capital, and year of establishment, is not disclosed.
If the current growth trend continues, revenue and operating profit are both expected to grow to levels exceeding previous expectations. The Company expects medium- to long-term growth in revenue and operating profit.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PDF-FD |
| Counterparty | SBCメディカルグループ (SBCメディカルグループ株式会社 and its group companies) |
| Counterparty overview | SBCメディカルグループ株式会社 and its group companies. Other information, including the location, representative, business activities, capital, and year of establishment, is not disclosed. |
| Relationship with the Company | Collaboration partner. Collaboration covers customer-base acquisition, integration of the sales channel, and expansion of processing capacity. |
| Applicable area | Medical Support business; blood-derived processing services |
| Quantitative Effects | Cumulative number of contracted blood-processing cases: 20,000. CAGR over the past 3 years: more than 99%, approximately eightfold. Number of partner clinics: 800 as of April 2026; CAGR over the past 3 years: more than 70%, more than fivefold. |
| Usage history | Cumulative number of contracted blood-processing cases: 20,000 (as of May 2026) |
| Impact on Business Performance | If the current growth trend continues, revenue and operating profit are both expected to grow to levels exceeding previous expectations. The Company expects medium- to long-term growth in revenue and operating profit. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The customer base is expanding, revenue opportunities are increasing through integrated production and sales, and processing capacity is being expanded through collaboration with SBCメディカルグループ. This is improving the ability to generate projects and alleviating supply constraints.